by Admin_Advicenne | 29 Sep 2021
Advicenne Reports 2021 Half Year Financial Results September 29, 2021 Paris, France, 29 September 2021 – 7:00AM (CEST) – Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those...
by Admin_Advicenne | 2 Jul 2021
Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of dRTA July 2, 2021 Paris, France, 2nd July 2021 – 7 am CEST – Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing...
by Admin_Advicenne | 23 Jun 2021
Advicenne successfully raises circa €9.4m in a placement reserved to a category of persons 1 2 The following pages contain information regarding the share capital increase of Advicenne. For regulatory reasons, the distribution of the content of such information is...
by Admin_Advicenne | 22 Jun 2021
Advicenne launches a reserved capital increase by means of an accelerated bookbuild offering for an amount of approx. EUR 10m 1 2 The following pages contain information regarding the share capital increase of Advicenne. For regulatory reasons, the distribution of the...
by Admin CP | 15 Jun 2021
Advicenne provides an update on its activities following its Annual General Meeting 17:45 p.m. CET, June 15, 2021 PARIS, France, 17:45 p.m. CET, June 15, 2021 – Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing...
